Medolife Rx And CURE Pharmaceutical Holding Corp. Collaborate For A Significant Increase Of Revenue
BURBANK, CA / ACCESSWIRE / February 23, 2021 / Medolife Rx, Inc., ("Medolife") a majority owned subsidiary of Quanta, Inc. (OTC PINK:QNTA), announced today that Medolife and CURE Pharmaceutical Holding Corp. ("CURE") signed a Collaboration and Joint Development Agreement on February 7, 2021. Medolife's polarization technology and CURE Pharmaceutical's CUREfilm® technology each had a strong market advantage prior to the multifaceted collaboration. Now, the collaboration of these unique, proprietary technologies is set to bring advanced pharmaceutical and nutraceutical-grade products to the consumer market.
"In quantum physics, one plus one does not equal two. Instead, it can be thousands and more. That is how we describe the beneficial outcome of this strategic collaboration. In a manner of speaking, our companies are making a quantum leap in revenue," said Medolife CEO, Dr. Arthur Mikaelian.
New Production Platform
Under the terms of the Collaboration and Joint Development Agreement, Medolife is investing into CURE to increase their production capabilities, while Medolife is receiving a production platform at CURE's manufacturing facility, located in Oxnard, California. This platform will be used for Medolife's pharmaceutical-grade products, such as their COVID-19 therapeutic, which is currently a US FDA Pre-Investigational New Drug (PIND #150335). In addition, Medolife is preparing for a US FDA application for their pancreatic cancer drug and a CBD topical cream to treat muscle pain, which will be produced within CURE's facility. More pharmaceutical-grade formulations are planned to follow.
Fully Licensed Facility
CURE's manufacturing facility currently holds production licenses for pharmaceuticals, nutraceuticals and cannabinoid-based products. It is also cGMP certified by the National Sanitation Foundation ("NSF") and adheres to the highest standards of quality. With the new production platform at CURE's manufacturing facility, Medolife can produce a wide variety of products, such as Medolife's COVID-19 therapeutic, cancer drugs and nutraceuticals like immune system enhancers, cosmetics, nootropics, stress relievers, and cannabinoid-based products.
Medolife Rx, Inc. is a Wyoming corporation, founded by Dr. Arthur Mikaelian, a pioneer of polarization technology, which has been awarded U.S. Patent 8,097,284 B2 as it pertains to Polarized Scorpion Venom solution and the method for making it. Dr. Mikaelian's technical education began at the 2nd Medical Institute of Moscow and continued at the Vernadsky University of Biosphere Knowledge in Moscow, where he earned his doctorate in Biological Psychology; he then went on to complete his post-doctorate work at Vernadsky. He also earned an MBA from the University of Bologna in Italy. You can find more about Medolife at: http://medolife.com/
Quanta, Inc. ("Quanta") utilizes a cutting-edge technology platform that applies advances in quantum biology to increase the potency of active ingredients. Currently, Quanta supports product formulations in pain management, anti-inflammation, skincare, agriculture, nutritional supplements, and plant-based consumables. Ultimately, Quanta's mission is to deliver better, more effective ingredients to elevate product efficacy, reduce waste and facilitate healthier, more sustainable consumption.
The established resonance theory behind polarization process used by Quanta has many potential applications. From potentiating bio-ingredients, to producing more-effective carbon-trapping plants, to transformative anti-aging solutions, Quanta has the opportunity to upend how commercial products are made and the benefits from them. Already, we see multitrillion dollar global industries benefiting from the technology used by Quanta. You can find more about Quanta at: https://buyquanta.com/.
About CURE Pharmaceutical Holding Corp.
CURE Pharmaceutical® is the pioneering developer of CUREform®, a patented drug delivery platform that offers a number of unique immediate- and controlled-release drug delivery vehicles designed to improve drug efficacy, safety, and patient experience for a wide range of active ingredients.
As a vertically integrated company, CURE's 25,000 square foot, FDA-registered, NSF® and cGMP-certified manufacturing facility enables it to partner with pharmaceutical and wellness companies worldwide for private and white-labeled production. CURE has partnerships in the U.S., China, Mexico, Canada, Israel, and other markets in Europe.
Safe Harbor Statement under the U.S. Private Securities Litigation Reform Act of 1995: This release contains statements that are forward-looking in nature which express the beliefs and expectations of management including statements regarding the Company's expected results of operations or liquidity; statements concerning projections, predictions, expectations, estimates or forecasts as to our business, financial and operational results and future economic performance; and statements of management's goals and objectives and other similar expressions concerning matters that are not historical facts. In some cases, you can identify forward-looking statements by terminology such as "anticipate," "estimate," "plan," "project," "continuing," "ongoing," "expect," "we believe," "we intend," "may," "will," "should," "could," and similar expressions. Such statements are based on current plans, estimates and expectations and involve a number of known and unknown risks, uncertainties and other factors that could cause the Company's future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. These factors and additional information are discussed in the Company's filings with the Securities and Exchange Commission and statements in this release should be evaluated in light of these important factors. Although we believe that these statements are based upon reasonable assumptions, we cannot guarantee future results. Forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to update publicly or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.
SOURCE: QUANTA, INC.
View source version on accesswire.com: